vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and PicoCELA Inc. (PCLA). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $252.6M, roughly 1.1× PicoCELA Inc.). Guardant Health, Inc. runs the higher net margin — -45.7% vs -125.2%, a 79.5% gap on every dollar of revenue. Guardant Health, Inc. produced more free cash flow last quarter ($-54.2M vs $-256.6M).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
PicoCELA Inc. is a global technology company specializing in low-power, high-reliability wireless connectivity solutions, including Wi-Fi HaLow modules and edge network infrastructure. It caters to industrial IoT, smart city, retail, and smart home segments, with a primary operational footprint across Asia, North America, and European markets.
GH vs PCLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $252.6M |
| Net Profit | $-128.5M | $-316.2M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | -114.8% |
| Net Margin | -45.7% | -125.2% |
| Revenue YoY | 39.4% | — |
| Net Profit YoY | -15.8% | — |
| EPS (diluted) | $-1.01 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | — | ||
| Q3 25 | $265.2M | — | ||
| Q2 25 | $232.1M | — | ||
| Q1 25 | $203.5M | $252.6M | ||
| Q4 24 | $201.8M | — | ||
| Q3 24 | $191.5M | — | ||
| Q2 24 | $177.2M | — | ||
| Q1 24 | $168.5M | — |
| Q4 25 | $-128.5M | — | ||
| Q3 25 | $-92.7M | — | ||
| Q2 25 | $-99.9M | — | ||
| Q1 25 | $-95.2M | $-316.2M | ||
| Q4 24 | $-111.0M | — | ||
| Q3 24 | $-107.8M | — | ||
| Q2 24 | $-102.6M | — | ||
| Q1 24 | $-115.0M | — |
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — | ||
| Q1 24 | 61.2% | — |
| Q4 25 | -43.0% | — | ||
| Q3 25 | -37.3% | — | ||
| Q2 25 | -45.9% | — | ||
| Q1 25 | -54.6% | -114.8% | ||
| Q4 24 | -62.4% | — | ||
| Q3 24 | -61.3% | — | ||
| Q2 24 | -56.8% | — | ||
| Q1 24 | -59.2% | — |
| Q4 25 | -45.7% | — | ||
| Q3 25 | -35.0% | — | ||
| Q2 25 | -43.0% | — | ||
| Q1 25 | -46.8% | -125.2% | ||
| Q4 24 | -55.0% | — | ||
| Q3 24 | -56.3% | — | ||
| Q2 24 | -57.9% | — | ||
| Q1 24 | -68.2% | — |
| Q4 25 | $-1.01 | — | ||
| Q3 25 | $-0.74 | — | ||
| Q2 25 | $-0.80 | — | ||
| Q1 25 | $-0.77 | — | ||
| Q4 24 | $-0.90 | — | ||
| Q3 24 | $-0.88 | — | ||
| Q2 24 | $-0.84 | — | ||
| Q1 24 | $-0.94 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $456.8M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $354.8M |
| Total Assets | $2.0B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | — | ||
| Q3 25 | $580.0M | — | ||
| Q2 25 | $629.1M | — | ||
| Q1 25 | $698.6M | $456.8M | ||
| Q4 24 | $525.5M | — | ||
| Q3 24 | $585.0M | — | ||
| Q2 24 | $933.7M | — | ||
| Q1 24 | $1.0B | — |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | — | ||
| Q3 25 | $-354.5M | — | ||
| Q2 25 | $-305.5M | — | ||
| Q1 25 | $-250.8M | $354.8M | ||
| Q4 24 | $-139.6M | — | ||
| Q3 24 | $-60.1M | — | ||
| Q2 24 | $-1.6M | — | ||
| Q1 24 | $68.3M | — |
| Q4 25 | $2.0B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $1.3B | $1.2B | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.6B | — | ||
| Q1 24 | $1.7B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $-245.6M |
| Free Cash FlowOCF − Capex | $-54.2M | $-256.6M |
| FCF MarginFCF / Revenue | -19.3% | -101.6% |
| Capex IntensityCapex / Revenue | 9.9% | 4.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | — | ||
| Q3 25 | $-35.4M | — | ||
| Q2 25 | $-60.3M | — | ||
| Q1 25 | $-62.7M | $-245.6M | ||
| Q4 24 | $-64.5M | — | ||
| Q3 24 | $-51.1M | — | ||
| Q2 24 | $-94.0M | — | ||
| Q1 24 | $-30.3M | — |
| Q4 25 | $-54.2M | — | ||
| Q3 25 | $-45.8M | — | ||
| Q2 25 | $-65.9M | — | ||
| Q1 25 | $-67.1M | $-256.6M | ||
| Q4 24 | $-83.4M | — | ||
| Q3 24 | $-55.3M | — | ||
| Q2 24 | $-99.1M | — | ||
| Q1 24 | $-37.2M | — |
| Q4 25 | -19.3% | — | ||
| Q3 25 | -17.3% | — | ||
| Q2 25 | -28.4% | — | ||
| Q1 25 | -33.0% | -101.6% | ||
| Q4 24 | -41.3% | — | ||
| Q3 24 | -28.9% | — | ||
| Q2 24 | -55.9% | — | ||
| Q1 24 | -22.1% | — |
| Q4 25 | 9.9% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | 2.4% | — | ||
| Q1 25 | 2.2% | 4.3% | ||
| Q4 24 | 9.4% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 2.9% | — | ||
| Q1 24 | 4.1% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
PCLA
| Revenue from product | $179.1M | 71% |
| Revenue from SaaS, Maintenance and others | $42.4M | 17% |
| Revenue from product – related party | $31.0M | 12% |
